Pharmaceutical Combination for Solid Tumor Elimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly for solid tumors like pancreatic adenocarcinoma, face challenges in effectively eliminating large tumors and achieving long-term immune memory due to complex immune resistance mechanisms and the suppressive tumor microenvironment, with checkpoint inhibitors and CAR-T therapies showing limited effectiveness.
Innovation Solution
A pharmaceutical combination comprising TLR ligands, compounds that label tumor cells for immune cell attack, anti-CD40 antibodies, and inhibitors of glutamine metabolism, such as resiquimod, polyinosinic: polycytidylic acid, mannan-BAM, and 6-diazo-5-oxo-norleucin, which work synergistically to enhance innate and adaptive immunity and restrict tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If checkpoint inhibitors are used to treat cancer, then immune response is enhanced, but effectiveness is limited to only about 20 percent of patients due to complex tumor defense mechanisms
Solution Approach 1:
The patent segments the complex immune resistance problem into multiple independent mechanisms and addresses each with specific therapeutic components: TLR ligands for innate immunity activation, compounds labeling tumor cells for immune recognition, anti-CD40 antibodies for adaptive immunity enhancement, and glutamine metabolism inhibitors for microenvironment modification. This multi-component approach systematically tackles the mosaic of tumor defense mechanisms that single checkpoint inhibitors cannot overcome.
Solution Approach 2:
The patent employs a composite immunotherapy approach by combining four distinct types of active substances into a single pharmaceutical composition. Each component contributes a different mechanism of action: TLR ligands activate pattern recognition receptors, labeling compounds mark tumor cells for destruction, anti-CD40 antibodies stimulate T-cell responses, and glutamine metabolism inhibitors disrupt tumor energy pathways. This composite strategy overcomes the limitations of monotherapies by addressing multiple immune resistance pathways simultaneously.
2Duration of action of moving object
If immunotherapy is used to treat large tumors and large metastases, then immune memory can be established, but complete elimination of the tumor is difficult or impossible with current therapies
Solution Approach 1:
The patent applies preliminary action by using compounds that label tumor cells with immunogenic markers before immune cell attack occurs. The labeling compounds prepare the tumor cells for enhanced recognition and destruction by immune cells, making them more visible and vulnerable to the combined immunotherapy regimen. This pre-marking step is crucial for enabling complete elimination of large tumor masses while maintaining the ability to establish long-term immune memory.
Data Source
AI summary
The object of the present invention is a pharmaceutical combination of active substances which comprises at least one TLR ligand, at least one compound that labels tumor cells as a target for immune cell attack and at least one anti-CD40 antibody, and further at least one inhibitor of glutamine metabolism. The use of the pharmaceutical combination is for cancer treatment, especially for solid tumor treatments as pancreatic adenocarcinoma.